en ENGLISH
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Bieżący numer Archiwum Filmy Artykuły w druku O czasopiśmie Suplementy Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
4/2020
vol. 122
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
streszczenie artykułu:
Wytyczne/zalecenia

Konsensus dotyczący stosowania cyklosporyny A u pacjentów z ciężkim zapaleniem rogówki w przebiegu zespołu suchego oka w okulistyce, reumatologii i hematologii

Leszek Borkowski
1
,
Dariusz Dobrowolski
2
,
Lidia Gil
3
,
Piotr Głuszko
4
,
Iwona Grabska-Liberek
5
,
Marta Misiuk-Hojło
6
,
Ewa Mrukwa-Kominek
7
,
Agnieszka Piekarska
8
,
Joanna Przeździecka-Dołyk
6, 9
,
Bożena Romanowska-Dixon
10
,
Jacek P. Szaflik
11
,
Bożena Targońska-Stępniak
12
,
Monika Udziela
11
,
Piotr Wiland
13

1.
Director’s plenipontiary for Drug Analysis and Management in Wolski Hospital, President of the foundation ”Razem w Chorobie” Board
2.
Department of Ophthalmology with Pediatric Unit, St Barbara 5th Regional Hospital in Sosnowiec, Poland
3.
Department of Haematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland
4.
Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
5.
Department of Ophthalmology, Medical Centre for Postgraduate Education, Warsaw, Poland
6.
Department of Ophthalmology, Wroclaw Medical University, Wroclaw, Poland
7.
Department of Ophthalmology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
8.
Department of Hematology and Transplantology, University Clinical Center, Medical University of Gdańsk, Gdańsk, Poland
9.
Department of Optics and Photonics, Faculty of Fundamental Problems of Technology, Wroclaw University of Science and Technology, Wroclaw, Poland
10.
Department of Ophthalmology and Ocular Oncology, University Hospital in Krakow, Poland
11.
Department of Ophthalmology, Medical University of Warsaw, Public Ophthalmic Teaching Hospital, Warsaw, Poland
12.
Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Lublin, Poland
13.
Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland
KLINIKA OCZNA 2020, 122, 4: 135–138
Data publikacji online: 2020/12/18
Pełna treść artykułu
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 

CONTENT OF THE CONSENSUS STATEMENT

In December 2019, clinical experts in the fields of ophthalmology, rheumatology and hematology held a meeting in order to develop guidelines for the prevention and treatment of severe forms of dry eye syndrome (DES). During the meeting, an extremely important therapeutic problem was highlighted; namely the lack of patient access to reimbursed cyclosporin A. In light of above, a Consensus Statement was drawn up regarding the unavailability of sight-saving therapy in the form of reimbursed cyclosporin A to patients with severe DES.
The Consensus Statement was developed with references to the latest guidelines for the treatment of DES, including Polish Ophthalmological Society 2018 [1], TFOS DEWS II [2-5], AAO 2018 [6], EULAR 2020 [7], EBMT 2019 [8], and the publication “Prevention and Treatment of Severe Keratitis in Dry Eye Syndrome” [9]. During the development of the experts’ position, the opinion of dr. n. farm. Leszek Borkowski was taken into account in the section addressing the safety of medicinal products with cyclosporin [10].
Dry eye syndrome is a complex disorder characterized by inflammation, and instability and hyperosmolarity of the tear film. Severe forms of DES can lead to significant damage to the structures of the ocular surface (including severe keratitis), and neurosensory abnormalities.
Even though DES significantly reduces the quality of life of patients, it tends to be trivialized as a public health problem, despite the condition being one of the most common reasons to see an ophthalmologist. When providing their medical history, patients typically report a range of persistent symptoms including burning sensation, discomfort, itching, visual disturbances, irritation, photosensitivity, gritty feeling in the eyes, excessive tearing, and difficulty reading, driving, and working at the computer. The seriousness of the health problem is reflected in the fact that the lack of patient access to reimbursed treatment contributes to progression of the disease, ultimately resulting in ocular damage. The longer the period from the onset of DES symptoms to the diagnosis, the higher the severity of daily discomfort and pain, and the greater the adverse impact of the disease on the overall quality of life and professional activity of patients. The negative effect of moderate to severe DES on the quality of life of affected individuals is comparable to that of conditions requiring...


Pełna treść artykułu...
facebook linkedin twitter
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe